Actinogen Medical has presented the scientific basis for its drug Xanamem, designed to reduce cortisol in the brain, as a treatment for Alzheimer's disease. Elevated cortisol is linked to cognitive decline, and Xanamem targets the enzyme 11β-HSD1 to lower cortisol levels. The drug has shown promising early results in mild Alzheimer's patients and healthy older adults. The company is conducting a pivotal trial with 247 participants, with results expected in November 2026, aiming to demonstrate that controlling brain cortisol can slow cognitive decline.
CarMax has partnered with Sierra to enhance its inbound sales call experience using Sierra's AI voice-enabled agents. Since May, these AI agents have helped customers reach the right destination or associate more quickly and consistently, improving c...
Paxel Financial Consulting, led by Chin Po, CPA, has joined LPL Financial’s broker-dealer and Registered Investment Advisor platform, bringing approximately $300 million in assets under management. The move aims to enhance client service through LPL’...
JPMorgan ETFs (Ireland) ICAV has declared dividends for various ETFs with ex-dividend dates starting August 13, 2026, record date August 14, and payment date September 4, 2026. The announcement lists dividend amounts per share for several funds, incl...
The healthcare chatbots market, valued at $1.02 billion in 2025, is projected to grow to $11.13 billion by 2035 with a CAGR of 27.05%. Growth is fueled by advances in generative AI, virtual healthcare adoption, EHR integration, and clinician shortage...
The glycolic acid market is projected to grow from $377.21 million in 2025 to $818.89 million by 2035, at an 8.06% CAGR. Growth is fueled by rising demand in cosmetics for exfoliation and anti-aging, as well as industrial uses like dyeing and tanning...
